Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Spanyolország
24 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Alicante, Barakaldo, Barcelona, Gijón, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Zaragoza
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 1/2. fázisTaking peopleDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
- Where
- Seville
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- ModeX Therapeutics, An OPKO Health Company
See details and how to joinNCT07249905 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- A Coruña, Badalona, Barcelona, Granada, Madrid, Oviedo, Palma, Pamplona, Pozuelo de Alarcón, Sabadell, Santander, Santiago de Compostela, Seville, Terrassa, Toledo, Valencia
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 1. fázisTaking peopleIKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Where
- Badalona, Madrid, Salamanca
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659 - No phaseTaking peoplePivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Where
- Madrid
- Életkor
- 10 év and over
- People
- 210 worldwide
- Run by
- Leuko Labs, Inc.
See details and how to joinNCT06323447 - 1. fázisTaking peopleA Study of ARC-02 in B-cell NHL
- Where
- Barcelona, Cáceres, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Barcelona, Esplugues De Llobregat, Madrid, Valencia
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisNot yet taking people in SpanyolországHOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
- Where
- DO NOT EDIT
- Életkor
- 65 év and over
- People
- 276 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524230-25-00 · EU 2025-524230-25-00 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Barcelona, Madrid, Majadahonda, Valencia
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 2. fázisTaking peopleResponse-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
- Where
- Badalona, Barcelona, Bilbao, Burgos, Cáceres, El Palmar, Madrid, Marbella, Oviedo, Palma de Mallorca, Salamanca, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 80
- Run by
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See details and how to joinNCT07126236 · EU 2024-514440-86-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Barcelona, Girona, Madrid, Majadahonda, Palma, Pamplona, Pozuelo de Alarcón, Sabadell, Salamanca, Santiago de Compostela, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - 1. fázisTaking peopleDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Barcelona, Gijón, Madrid
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Sevilla
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - No phaseTaking peopleReal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
- Where
- A Coruña, Badalona, Burgos, Córdoba, Manises, Marbella, Murcia, Pamplona, Sabadell, Santa Cruz de Tenerife, Seville, Valladolid
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AbbVie
See details and how to joinNCT06830759 - 1. fázisTaking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
- Életkor
- 18 év and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - 2. fázisTaking peopleStudy to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
- Where
- A Coruña, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Murcia, Palma de Mallorca, Pamplona, Salamanca, San Sebastián, Santander, Seville, Valencia
- Életkor
- 18 év and over
- People
- 45
- Run by
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See details and how to joinNCT07254754 - 1/2. fázisTaking peopleA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
- Where
- Barcelona, Madrid, Murcia, Salamanca, Santander, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 37
- Run by
- IDP Discovery Pharma S.L.
See details and how to joinNCT05908409 - 2. fázisTaking peopleLATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
- Where
- A Coruña, Barcelona, Donostia, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Salamanca, Santander, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 45
- Run by
- Fundacion Geltamo
See details and how to join2024-512835-53-00 · EU 2024-512835-53-00 - No phaseTaking peopleStudy of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
- Where
- Salamanca
- Életkor
- 18 év and over
- People
- 40
- Run by
- Instituto de Investigación Biomédica de Salamanca
See details and how to joinNCT06439173 - 2. fázisTaking peopleDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Where
- Barcelona, Burgos, Seville
- Életkor
- 18 év and over
- People
- 102 worldwide
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617 - 1/2. fázisTaking peoplePhase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, Valencia
- Életkor
- 18 év to 64 év
- People
- 37 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00